JP2024524527A5 - - Google Patents
Info
- Publication number
- JP2024524527A5 JP2024524527A5 JP2024500088A JP2024500088A JP2024524527A5 JP 2024524527 A5 JP2024524527 A5 JP 2024524527A5 JP 2024500088 A JP2024500088 A JP 2024500088A JP 2024500088 A JP2024500088 A JP 2024500088A JP 2024524527 A5 JP2024524527 A5 JP 2024524527A5
- Authority
- JP
- Japan
- Prior art keywords
- bispecific antibody
- intact
- antibody
- cells
- intact bispecific
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21183796 | 2021-07-05 | ||
| EP21183796.8 | 2021-07-05 | ||
| EP21184105.1A EP4116330A1 (en) | 2021-07-05 | 2021-07-06 | Multispecific antibodies with monovalent binding to tumor-associated antigens causing no or reduced nerve pain in the treatment of cancer |
| EP21184105.1 | 2021-07-06 | ||
| PCT/EP2022/068634 WO2023280880A1 (en) | 2021-07-05 | 2022-07-05 | Multispecific antibodies binding to tumor-associated antigens causing no or reduced nerve pain in the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024524527A JP2024524527A (ja) | 2024-07-05 |
| JP2024524527A5 true JP2024524527A5 (enExample) | 2025-05-12 |
Family
ID=82656531
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024500088A Pending JP2024524527A (ja) | 2021-07-05 | 2022-07-05 | がん治療において神経疼痛の消失または軽減をもたらす腫瘍関連抗原に結合する多重特異性抗体 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20240239916A1 (enExample) |
| EP (1) | EP4330289A1 (enExample) |
| JP (1) | JP2024524527A (enExample) |
| WO (1) | WO2023280880A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024040195A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| AU2024279278A1 (en) | 2023-05-31 | 2025-12-18 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| IL327045A (en) | 2023-10-05 | 2026-05-01 | Capstan Therapeutics Inc | Structure-restricted ionizable cationic lipids and lipid nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| EP4684803A1 (en) | 2024-07-25 | 2026-01-28 | CeMM - Forschungszentrum für Molekulare Medizin GmbH | Antibody conjugated chemical inducers of degradation of rbm39 and therapeutic uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE122009000068I2 (de) | 1994-06-03 | 2011-06-16 | Ascenion Gmbh | Verfahren zur Herstellung von heterologen bispezifischen Antikörpern |
| CA2414148A1 (en) * | 2002-12-30 | 2004-06-30 | William Herman | Targeted ligands |
| WO2013189516A1 (en) * | 2012-06-18 | 2013-12-27 | Apeiron Biologics Ag | Method for treating a gd2 positive cancer |
| US11820832B2 (en) * | 2014-07-25 | 2023-11-21 | Memorial Sloan Kettering Cancer Center | Bispecific HER2 and CD3 binding molecules |
| KR102638104B1 (ko) * | 2014-07-25 | 2024-02-20 | 메모리얼 슬로안 케터링 캔서 센터 | 이특이적 her2 및 cd3 결합 분자 |
| TWI823906B (zh) * | 2018-03-09 | 2023-12-01 | 美商艾吉納斯公司 | 抗-cd73 抗體及其使用方法 |
-
2022
- 2022-07-05 EP EP22744699.4A patent/EP4330289A1/en active Pending
- 2022-07-05 US US18/577,197 patent/US20240239916A1/en active Pending
- 2022-07-05 WO PCT/EP2022/068634 patent/WO2023280880A1/en not_active Ceased
- 2022-07-05 JP JP2024500088A patent/JP2024524527A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Folli et al. | Tumor‐necrosis factor can enhance radio‐antibody uptake in human colon carcinoma xenografts by increasing vascular permeability | |
| JP2011507932A5 (enExample) | ||
| US6444207B1 (en) | Immunotherapy of tumor with monoclonal antibody against the 17-1A antigen | |
| JPS5843926A (ja) | 選択性制癌剤 | |
| US20240307541A1 (en) | Methods for local and systemic treatment of cancers, tumors and tumor cells | |
| IL184803A (en) | Purified antibodies against epha2, methods for their production, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for treating cancer | |
| WO2021182573A1 (ja) | 癌の治療及び／又は予防のための医薬品 | |
| US20220313822A1 (en) | Near-infrared (nir) photoimmunotherapy (pit) for the treatment of cancers using anti-cd25 antibody-phthalocyanine dye conjugate and anti-pd1 antibody | |
| JPH06501705A (ja) | 抗−腫瘍抗体及び生物学的活性剤の組合せによる相乗治療 | |
| TW202330040A (zh) | 抗ｈｅｒ２抗體藥物偶聯物和酪胺酸激酶抑制劑聯合在製備治療腫瘤的藥物中的用途 | |
| CN1342096A (zh) | 组胺诱导的协同破坏肿瘤作用 | |
| JP2634218B2 (ja) | Ａｄｃｃ療法を高める組成物 | |
| JPH01502909A (ja) | 免疫毒素による人間の治療における免疫抑制 | |
| IL305095A (en) | Use of a HER2-targeted antibody-drug conjugate in the treatment of specific breast cancer | |
| WO2021182571A1 (ja) | 癌の治療及び／又は予防のための医薬品 | |
| US6007807A (en) | Induction of tumour immunity by injection of hybrid cells | |
| Tempero et al. | Immunotherapy with monoclonal antibody (Mab) in pancreatic adenocarcinoma | |
| Mulshine et al. | In vivo diagnosis and therapy of human tumors with monoclonal antibodies: Selection of antibodies and preliminary clinical studies in small cell carcinoma of the lung | |
| Rickmann | Naxitamab. Humanized anti-GD2 ganglioside monoclonal antibody, Treatment of high-risk neuroblastoma | |
| WO2025056070A1 (zh) | 一种治疗肿瘤的组合疗法及其应用 | |
| Otsuji et al. | Biodistribution of monoclonal antibody A7 and its F (ab′) 2 fragment in athymic nude mice bearing human pancreatic carcinoma | |
| CN103041387B (zh) | 恶性b细胞淋巴瘤抗体药物的新用途 | |
| JPH0193538A (ja) | 抗腫瘍剤 | |
| RU2023134007A (ru) | Применение конъюгата антитело-лекарственное средство в комбинации с ингибитором иммунных контрольных точек в лечении уротелиального рака | |
| Triozzi et al. | Clinical and immunologic effects of monoclonal antibody CC49 and interleukin-2 in patients with metastatic colorectal cancer |